Sjögren's disease trials in Germany
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleTwo Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Where
- Berlin, Dresden, Erlangen, Freiburg im Breisgau, Gommern, Herne, Meerbusch, Munich, Ratingen, Rendsburg, Sendenhorst
- Age
- 18 years and over
- People
- 570 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07621809 · EU 2025-522271-29-00 - Phase 2Taking peopleA Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
- Where
- Cologne, Dresden, Freiburg im Breisgau, Herne, Meerbusch, Ratingen
- Age
- 18 years to 100 years
- People
- 344 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07737743 · EU 2025-524513-92-00 - Phase 3Taking peoplePhase 3 Study of Telitacicept in Active Primary Sjögren's Disease
- Where
- Bad Bramstedt, Cologne, Dresden, Erlangen, Herne, Munich, Ratingen
- Age
- 18 years to 75 years
- People
- 250 worldwide
- Run by
- Vor Biopharma
See details and how to joinNCT07404865 · EU 2026-525556-28-00 - Phase 1Not yet taking people in GermanyA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Berlin, Erlangen, Magdeburg, Würzburg
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - Phase 2Not yet taking people in GermanyA Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
- Where
- Freiburg im Breisgau, Hanover, Munich
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- argenx
See details and how to joinNCT07760818 · EU 2026-526218-10-00 - Phase 1Taking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- Where
- Erlangen, Hanover
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT07041099 - Phase 2Taking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Bonn, Munich
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - Phase 1Taking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Cologne, Duesseldorf, Jena, Mainz
- Age
- 18 years to 70 years
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - Phase 1Taking peopleA Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
- Where
- Erlangen, Hanover
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to join2025-521462-96-00 · EU 2025-521462-96-00 - Phase 3Taking peopleA Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Where
- Bad Doberan, Greifswald, Hamburg, Heidelberg
- Age
- 18 years and over
- People
- 844 worldwide
- Run by
- Amgen
See details and how to joinNCT06747949 · EU 2024-517513-32-00